6/29/23, 1:09 AM RECOVERY (aspirin) Pathway Feedback Search Clinical Topics Home Studies RECOVERY (aspirin) RECOVERY (aspirin) Disease COVID 19 infection Trial question What is the role of aspirin in hospitalized patients with COVID-19? Study design Multi-center Open label RCT Population Characteristics of study participants 38.0% female N = 14892 62.0% male 14892 patients (5691 female, 9201 male) Inclusion criteria: adults hospitalized with COVID-19 Key exclusion criteria: age < 18 years; hypersensitivity to aspirin; a recent history of major bleeding; receipt of aspirin; antiplatelet treatment Interventions N=7351 aspirin (usual standard of care plus 150 mg aspirin daily until discharge) N=7541 usual care (usual standard of care alone) Primary outcome Death at day 28 17.0 % 17 17 https://web.pathway.md/studies/rect8fNWragMmTXoG 1/2 6/29/23, 1:09 AM RECOVERY (aspirin) Pathway 12.8 % 8.5 % 4.3 % No significant difference 0.0 % Aspirin Usual care No significant difference in death at day 28 (17% vs. 17%; RR 0.96, 96% CI 0.89 to 1.04) Secondary outcomes Significant increase in alive discharges from the hospital at day 28 (75% vs. 74%; RR 1.06, 95% CI 1.02 to 1.1) No significant difference in invasive mechanical ventilation or death (21% vs. 22%; RR 0.96, 96% CI 0.9 to 1.03) No significant difference in invasive mechanical ventilation (11% vs. 12%; RR 0.95, 95% CI 0.87 to 1.05) Safety outcomes No significant differences in thrombotic events, new cardiac arrhythmias. Significant difference in major bleeding (1.6% vs. 1.0%). Conclusion In adults hospitalized with COVID-19, aspirin was not superior to usual care with respect to death at day 28. Reference RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022 Jan 8;399(10320):143-151. Open reference URL https://web.pathway.md/studies/rect8fNWragMmTXoG 2/2